168 related articles for article (PubMed ID: 28012777)
1. Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
Schaedler E; Remy-Ziller C; Hortelano J; Kehrer N; Claudepierre MC; Gatard T; Jakobs C; Préville X; Carpentier AF; Rittner K
Vaccine; 2017 Jan; 35(4):577-585. PubMed ID: 28012777
[TBL] [Abstract][Full Text] [Related]
2. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
3. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
[TBL] [Abstract][Full Text] [Related]
5. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
[TBL] [Abstract][Full Text] [Related]
8. Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
Claudepierre MC; Hortelano J; Schaedler E; Kleinpeter P; Geist M; Remy-Ziller C; Brandely R; Tosch C; Laruelle L; Jawhari A; Menguy T; Marchand JB; Romby P; Schultz P; Hartmann G; Rooke R; Bonnefoy JY; Preville X; Rittner K
J Virol; 2014 May; 88(10):5242-55. PubMed ID: 24574403
[TBL] [Abstract][Full Text] [Related]
9. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
10. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
11. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
12. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
14. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
15. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
Dreicer R; Stadler WM; Ahmann FR; Whiteside T; Bizouarne N; Acres B; Limacher JM; Squiban P; Pantuck A
Invest New Drugs; 2009 Aug; 27(4):379-86. PubMed ID: 18931824
[TBL] [Abstract][Full Text] [Related]
16. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.
Tosch C; Bastien B; Barraud L; Grellier B; Nourtier V; Gantzer M; Limacher JM; Quemeneur E; Bendjama K; Préville X
J Immunother Cancer; 2017 Sep; 5(1):70. PubMed ID: 28923084
[TBL] [Abstract][Full Text] [Related]
17. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
18. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
20. TG4010: a vaccine with a therapeutic role in cancer.
Arriola E; Ottensmeier C
Immunotherapy; 2016 May; 8(5):511-9. PubMed ID: 27140406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
